Kininogen-1 (Kng1), partial, rat, recombinant

Organism: Rattus norvegicus (Rat). Source: Yeast. Expression Region: 390-639aa. Protein Length: Partial. Tag Info: N-terminal 6xHis-tagged. Target Protein Sequence: APRVKKPKES TTVSPSYIAR VQEERDPGNE QGPIHGHGWL HAKQIKNKNH QGHKHGHGIG HGHQKPHGLG HGHQLKLDDL KQQREDGYDH RHPVGHGHGQ RHGHGHGHGH GRDKHTNKDK NNVKHTDQRR APLTSSSEDN TTSTQIQGRT EGFTLNPPLA QPAVISRGFQ DSGFTEGVIA TTSPYDTETH DDLIPDIHVQ PDSLSFKLIS DFPEATSHKC PGRPWKPVSR KDPTIETTEF SDFDLLDALS. Purity: Greater than 90% as determined by SDS-PAGE. Endotoxin: Not test. Biological Activity: n/a. Form: Liquid or Lyophilized powder. Buffer: If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0. Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20 °C/-80 °C. Our default final concentration of glycerol is 50%. Customers could use it as reference. Storage: The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself. Generally, the shelf life of liquid form is 6 months at -20 °C/-80 °C. The shelf life of lyophilized form is 12 months at -20 °C/-80 °C. Notes: Repeated freezing and thawing is not recommended. Store working aliquots at 4 °C for up to one week. Relevance: 1 Kininogens are inhibitors of thiol proteases, (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII, (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes, (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action), (5) LMW-kininogen inhibits the aggregation of thrombocytes, (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting. Reference: Differing expression patterns and evolution of the rat kininogen gene family.Kitagawa H., Kitamura N., Hayashida H., Miyata T., Nakanishi S.J. Biol. Chem. 262:2190-2198(1987). Function: (1) Kininogens are inhibitors of thiol proteases, (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII, (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes, (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects